Novartis: Leqvio Provides Low-density Lipoprotein Cholesterol Reduction Beyond 6 Years Of Treatment

Novartis reported long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data showed that with twice-yearly dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol reduction beyond six years in patients with atherosclerotic cardiovascular disease, increased risk of ASCVD or heterozygous familial hypercholesterolemia.